

Meet The Professors

A case-based discussion on the management
of lung cancer in the adjuvant
and metastatic settings



EDITOR

Neil Love, MD

FACULTY

Martin J Edelman, MD

Thomas J Lynch, MD

Alan B Sandler, MD

Mark A Socinski, MD



Subscribe to Podcasts
or download MP3s
of this program at
MeetTheProfessors.com

from the publishers of

Lung Cancer[™]
UPDATE



Meet The Professors: A case-based discussion on the management of lung cancer in the adjuvant and metastatic settings

STATEMENT OF NEED/TARGET AUDIENCE

Lung cancer is the leading cause of cancer mortality in the United States in both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been modest, and about 85 percent of patients who develop lung cancer will die from it. In addition, a sense of therapeutic nihilism has pervaded the medical community in the past. Chemotherapy, surgery and radiation therapy have had a modest effect on patient outcomes; however, recent improvements have been seen in time to progression and survival in lung cancer clinical trials. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. In order to incorporate research advances into developing treatment strategies for patients, the CME program *Meet The Professors* utilizes case-based discussions between community oncologists and clinical investigators.

LEARNING OBJECTIVES

- Critically evaluate the clinical implications of emerging clinical trial data in lung cancer treatment and incorporate these data into management strategies in the adjuvant, neoadjuvant, locally advanced and metastatic settings.
- Counsel appropriately selected patients about the availability of ongoing clinical trials.
- Develop and explain a management strategy for treatment of elderly patients and those with poor performance status in the adjuvant, neoadjuvant, locally advanced and metastatic settings.
- Integrate emerging data on utilization of targeted molecular therapies and molecular and genetic assays in the development of individual management strategies for patients with lung cancer.
- Counsel patients with localized primary lung cancer about the risks and benefits of adjuvant chemotherapy.
- Identify the impact of smoking-related comorbidities on the treatment of patients with lung cancer and integrate smoking cessation into the management strategy for these patients.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 2.75 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the CME information and complete the Evaluation Form located in the back of this book or on our website, MeetTheProfessors.com.

Faculty Affiliations



Martin J Edelman, MD
Professor of Medicine
Director of Medical
Thoracic Oncology
University of Maryland
Greenebaum Cancer Center
Baltimore, Maryland



Alan B Sandler, MD
Associate Professor of
Medicine; Medical Director
Thoracic Oncology; Director
Vanderbilt-Ingram Cancer
Center Affiliate Network
Program, Vanderbilt
University Medical Center
Division of Hematology/
Oncology
Nashville, Tennessee



Thomas J Lynch, MD
Director, MGH Thoracic
Oncology Center
Deputy Chief
Hematology Oncology
Associate Professor
of Medicine
Massachusetts
General Hospital
Boston, Massachusetts



Mark A Socinski, MD
Associate Professor
of Medicine
Multidisciplinary Thoracic
Oncology Program
Lineberger Comprehensive
Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Medical Oncologist Community Panel

Howard R Abel, MD
Ft Lauderdale, Florida

Samuel N Bobrow, MD
New Haven, Connecticut

Margaret A Deusch, MD
Raleigh, North Carolina

Atif M Hussein, MD
Hollywood, Florida

Noor M Merchant, MD
Sebastian, Florida

Kenneth K Ng, MD
Rockville Centre, New York

William G Reeves, MD
Youngstown, Ohio

Kert D Sabbath, MD
Bethany, Connecticut

Mark A Taylor, MD
Savannah, Georgia

Paul L Weinstein, MD
Stamford, Connecticut

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Chris Thomson, MD, MS, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech Inc/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Edelman — **Consulting Fees:** Abraxis Oncology, Pharmacyclics, Sanofi-Aventis; **Other:** Abraxis Oncology, Sanofi-Aventis. **Dr Lynch** — **Honoraria:** AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech Inc, OSI Pharmaceuticals, Sanofi-Aventis; **Consulting Fees:** Genentech Inc, Millennium Pharmaceuticals Inc, OSI Pharmaceuticals, Telik Inc; **Advisor:** Hana Biosciences Inc, ImClone Systems, Sanofi-Aventis. **Dr Sandler** — **Consulting Fees:** Genentech Inc, Sanofi-Aventis; **Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents:** Genentech Inc; **Contracted Research:** Genentech Inc, Sanofi-Aventis. **Dr Socinski** — **Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents:** Abraxis Oncology, Genentech Inc, Sanofi-Aventis; **Contracted Research:** Abraxis Oncology, Genentech Inc, Sanofi-Aventis.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

Case Studies

Case 1: An active 78-year-old woman with adenocarcinoma and bronchoalveolar features (*from the practice of Dr William G Reeves*)

Case 2: A 69-year-old woman with metastatic, poorly differentiated adenocarcinoma and a four-year response to six cycles of adjuvant carboplatin/paclitaxel (*from the practice of Dr Atif M Hussein*)

Case 3: A prior oligosmoker in her sixties, diagnosed with Stage IV adenocarcinoma, who enrolled in CALGB-30406 and was assigned to treatment with carboplatin/paclitaxel/erlotinib (*from the practice of Dr Mark A Taylor*)

Case 4: A 65-year-old woman with Stage IIIB multifocal bronchoalveolar carcinoma (*from the practice of Dr Howard R Abel*)

Case 5: A 68-year-old female nonsmoker with recurrent pleural effusions secondary to metastatic non-small cell lung cancer (NSCLC) (*from the practice of Dr Kert D Sabbath*)

Case 6: An 85-year-old woman with a performance status of 1-2 and Stage IIIB adenocarcinoma (*from the practice of Dr Noor M Merchant*)

Case 7: A 61-year-old female nonsmoker with Stage IV NSCLC (*from the practice of Dr Noor M Merchant*)

Case 8: An asymptomatic 58-year-old female nonsmoker with brain metastases secondary to adenocarcinoma (*from the practice of Dr Samuel N Bobrow*)

Case 9: A 64-year-old man s/p lobectomy for a four-centimeter Stage IB adenocarcinoma (*from the practice of Dr Samuel N Bobrow*)

Case 10: A 45-year-old female nonsmoker with Stage IIIB adenocarcinoma and palpable supraclavicular adenopathy (*from the practice of Dr Paul L Weinstein*)

Guide to Audio Program

Compact Disc 1: Tracks 1-4 — case from Dr Reeves; Tracks 5-14 — case from Dr Hussein; Tracks 15-21 — case from Dr Taylor

Compact Disc 2: Tracks 1-2 — case from Dr Abel; Tracks 3-4 — case from Dr Sabbath; Tracks 5-7 — cases from Dr Merchant; Tracks 8-12 — cases from Dr Bobrow; Tracks 13-21 — case from Dr Weinstein

Evaluation Form: *Meet The Professors* Lung Cancer, Issue 1, 2006

Research To Practice respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please complete this evaluation form. A certificate of completion will be issued upon receipt of your completed evaluation form.

Please answer the following questions by circling the appropriate rating:

5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor N/A = Not applicable to this issue of *MTP*

GLOBAL LEARNING OBJECTIVES

To what extent does this issue of *MTP* address the following global learning objectives?

- Critically evaluate the clinical implications of emerging clinical trial data in lung cancer treatment and incorporate these data into management strategies in the adjuvant, neoadjuvant, locally advanced and metastatic settings. 5 4 3 2 1 N/A
- Counsel appropriately selected patients about the availability of ongoing clinical trials. 5 4 3 2 1 N/A
- Develop and explain a management strategy for treatment of elderly patients and those with poor performance status in the adjuvant, neoadjuvant, locally advanced and metastatic settings. 5 4 3 2 1 N/A
- Integrate emerging data on utilization of targeted molecular therapies and molecular and genetic assays in the development of individual management strategies for patients with lung cancer. 5 4 3 2 1 N/A
- Counsel patients with localized primary lung cancer about the risks and benefits of adjuvant chemotherapy. 5 4 3 2 1 N/A
- Identify the impact of smoking-related comorbidities on the treatment of patients with lung cancer and integrate smoking cessation into the management strategy for these patients. 5 4 3 2 1 N/A

EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

| Faculty | Knowledge of subject matter | Effectiveness as an educator |
|----------------------|-----------------------------|------------------------------|
| Martin J Edelman, MD | 5 4 3 2 1 | 5 4 3 2 1 |
| Thomas J Lynch, MD | 5 4 3 2 1 | 5 4 3 2 1 |
| Alan B Sandler, MD | 5 4 3 2 1 | 5 4 3 2 1 |
| Mark A Socinski, MD | 5 4 3 2 1 | 5 4 3 2 1 |

OVERALL EFFECTIVENESS OF THE ACTIVITY

| | | | | | |
|--|---|---|---|---|---|
| Objectives were related to overall purpose/goal(s) of activity | 5 | 4 | 3 | 2 | 1 |
| Related to my practice needs | 5 | 4 | 3 | 2 | 1 |
| Will influence how I practice | 5 | 4 | 3 | 2 | 1 |
| Will help me improve patient care | 5 | 4 | 3 | 2 | 1 |
| Stimulated my intellectual curiosity | 5 | 4 | 3 | 2 | 1 |
| Overall quality of material | 5 | 4 | 3 | 2 | 1 |
| Overall, the activity met my expectations | 5 | 4 | 3 | 2 | 1 |
| Avoided commercial bias or influence | 5 | 4 | 3 | 2 | 1 |

Which of the following audio formats of this program did you use?

- Audio CDs Downloaded MP3s from website

Evaluation Form: *Meet The Professors* Lung Cancer, Issue 1, 2006

REQUEST FOR CREDIT — Please Print Clearly

Name: Specialty:
Degree: MD DO PharmD NP BS RN PA Other
Medical License/ME Number: Last 4 digits of SSN# (required):
Street Address:
Box/Suite: City, State, Zip:
Phone Number: Fax Number:
Email:

Research To Practice designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be ____ hour(s).

Signature: Date:

Will the information presented cause you to make any changes in your practice?

Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity.

.....

What other topics would you like to see addressed in future educational programs?

.....

What other faculty would you like to hear interviewed in future educational programs?

.....

Additional comments about this activity:

.....

FOLLOW - UP

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

Yes, I am willing to participate in a follow-up survey. No, I am not willing to participate in a follow-up survey.

To obtain a certificate of completion and receive credit for this activity, please fill out the Evaluation Form and mail or fax to: Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131, FAX 305-377-9998. You may also complete the Evaluation online at MeetTheProfessors.com/CME.

Meet The Professors

| | |
|---|--|
| Editor/CME Director | Neil Love, MD |
| Managing Editor | Kathryn Ault Ziel, PhD |
| Scientific Director | Richard Kaderman, PhD |
| Writers | Lilliam Sklaver Poltorack, PharmD Douglas Paley |
| Continuing Education Administrator for Nursing | Sally Bogert, RNC, WHCNP |
| Content Validation | Margaret Peng Ginelle Suarez Erin Wall |
| Director, Creative and Copy Editing | Aura Herrmann |
| Creative Manager | Fernando Rendina |
| Graphic Designers | Jason Cunniss Shantia Daniel Elisa Stambouli |
| Senior Production Editor | Alexis Oneca |
| Managing Production Coordinator | Tere Sosa |
| Copy Editors | Dave Amber Mary DiNunzio Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke Susan Petrone |
| Production Manager | Patricia Kappes |
| Audio Production | Frank Cesarano |
| Technical Services | Arly Ledezma |
| Web Master | John Ribeiro |
| Contact Information | Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.net |
| For CME Information | Email: CME@ResearchToPractice.net |

Copyright © 2006 Research To Practice. All rights reserved.

This program is supported by an education grant from Genentech Inc.

The compact discs, internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Copyright © 2006 Research To Practice.
This program is supported by an education grant from
Genentech Inc.



Sponsored by Research To Practice.

Last review date: December 2006
Release date: December 2006
Expiration date: December 2007
Estimated time to complete: 2.75 hours